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Gamma interferon (IFNγ) was discovered in 1965 as an antiviral
activity in white blood cell cultures stimulated with the lympho-
cyte mitogen phytohemagglutinin (1). At that time, IFNγ, as was
the case with the much earlier discovered type I IFNs, was thought
to strictly function as an antiviral. It was noted, however, that IFNγ
was more sensitive than type I IFNs to extremes of pH and tem-
peratures of 56°C or higher, a suggestion that it was a different
kind of IFN.
We played a key role in the first demonstration that IFNγ
along with the type I IFNs regulated immune functions (2–
4). These discoveries were confirmed and extended by others,
making IFNs the first well-characterized cytokines. The reviews
presented here provide important insight into our current under-
standing of the structural basis of the mechanism of specific
gene activation by IFNγ, how its activity is regulated by immune
modulators called suppressors of cytokine signaling (SOCS) and
regulatory T cells, its effector role in autoimmunity, and how it
functions as a key factor in host defense against viral and parasitic
diseases.
The first three articles deal, respectively, with a non-canonical
model of IFNγ signaling (5), the role of IFNγ receptor in such
signaling (6), as well as epigenetic aspects of activation of the IFNγ
gene (7). SOCS and regulatory T cells (Tregs) play the key role
as governors of signaling by cytokines such as IFNγ. Too much
regulation can be detrimental in immune regulation of diseases
such as cancer while too little can result in autoimmune disease.
Thus, the fourth article addresses cross-talk between SOCS1 and
Tregs in the context of regulation of IFNγ (8). The cross-talk
between the systems is a novel observation with SOCS1 playing
the hierarchical role.
With respect to viral diseases, IFNγ is discussed in the con-
text of human immunodeficiency virus-1 (HIV-1) (9) and herpes
simplex virus-1 (HSV-1) (10). These are difficult viruses to con-
trol in an infectious setting. HSV-1 attacks the immune system
as well as the central nervous system (CNS). The HIV-1 review
points out the complex relationship between IFNγ and this virus
where both therapeutic as well as exacerbative effects on HIV-1
pathogenesis have been attributed to IFNγ. HSV-1 is a difficult,
persistent neurotropic infectious virus. The relationship of IFNγ
to HSV-1 pathogenesis is defined more clearly than is the case for
HIV-1. For example, IFNγ plays a key role in preventing the virus
from exiting the latency state.
IFNγ is a key player in regulation of protective immunity
against blood-stage malaria, and this is discussed in the context
of gamma/delta T cells (11). Specifically, certain gamma/delta
T cells produce IFNγ after Plasmodium infection, which is shown
to be involved in dendritic cell reduction of Plasmodium parasites
in the blood. IFNγ is probably the key cytokine in host defense
against Leishmania infections in general although different Leish-
mania species may respond differently against this cytokine (12).
Even so, IFNγ appears to function cooperatively with chemokines
such as CXCL10 in CD8+ T cell response to Leishmania-infected
cells.
Finally, IFNγ as well as type I IFNs may function cooperatively
in promotion of Sjogren’s syndrome as shown by upregulation
of IFN response genes (IRGs) (13). Sjogren’s syndrome is charac-
terized by chronic immune attacks against exocrine glands (such
as salivary glands) leading to exocrine dysfunction. An SOCS1
mimetic plays an important role in inhibiting the inflamma-
tory aspect of autoimmune diseases such as multiple sclerosis
as pointed out in the fourth review (8). Thus, given the impor-
tance of the IFNs in Sjogren’s syndrome, it would seem that
it would be a candidate for potential SOCS1 mimetic therapy
based on the experience with other autoimmune diseases. The
SOCS and Sjogren’s syndrome reviews as well as others pre-
sented here, therefore, are interrelated in terms of approaches to
dealing with diseases where IFNγ may play either a positive or
negative role.
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